Summit Therapeutics Inc.
SMMTBiotechnology
$16.03−1.05%As of Oct 30vs prior close
- Market cap
- $12.8B
- P/E (TTM)
- –
- From 52W high
- −39.23%
- EPS (LTM)
- -$1.44
- Revenue (YE24)
- $0
Nomior Score
34
Steady ProfileBottom 20% of the scored universe
Growth61
Quality32
Value37
Momentum35
Resilience42
Growth
$0revenue, YE24
YE19 $57.1MYE24 $0
Connections
Revenue to profitYE22
The operating loss was 10225% of revenue, wider by 5461 pts on a year.
Who owns it
1fund